Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs KKR & Co Inc (KKR) Price & Performance

Davita IncTrade
KKR & Co IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs KKR & Co Inc — how do they compare? Davita Inc trades at $178.35 (market cap $11.38B), while KKR & Co Inc trades at $111 (market cap $99.61B). The key difference: KKR & Co Inc is far larger — about 8.8× Davita Inc's market cap, and KKR & Co Inc pays a 0.7% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

DVAKKR
Market Cap
$11.38B$99.61B
Sector
HealthFinancials
52-Week High
$240.96$149.34
52-Week Low
$103.87$83.88
Enterprise Value
$24.10B$22.17B
Dividend Yield
0.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.

The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.

KKR & Co Inc

KKR trades at $110.625, up 6.54% today, with strong bullish momentum near its consensus price target of $127.22. Recent earnings beats in Q1 and Q2 2026, alongside a high analyst buy rating of 88.89%, reflect robust operational performance. The company's strategic acquisitions, including Medicover India and Integer Holdings, signal aggressive growth in healthcare and infrastructure sectors.

The outlook for KKR is positive, driven by earnings growth and strategic expansions, but risks include high leverage and market volatility. Upside potential exists if the company maintains its earnings trajectory and executes acquisitions successfully, though investors should monitor debt levels and integration challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About KKR & Co Inc

KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.

Read more on KKR